Literature DB >> 21041901

The natural history of chronic HBV infection and geographical differences.

Yun-Fan Liaw1, Maurizia R Brunetto, Stephanos Hadziyannis.   

Abstract

Although chronic HBV infection is a global health issue, there are geographical differences in the mode of transmission, prevalence and HBV genotype distribution. Chronic HBV infection is a dynamic state of interactions between HBV, hepatocytes and immune cells of the host. Accordingly, the natural history of chronic HBV infection typically starts with an immune tolerant phase, followed by an immune clearance phase and finally an inactive phase. The duration of the immune tolerant phase is usually long in chronic HBV infection acquired perinatally or in early childhood, otherwise the duration is very short. During the inactive phase, spontaneous hepatitis B surface antigen (HBsAg) seroclearance might occur at an annual rate of 1-2%; however, HBV reactivation with hepatitis activity could occur over time in one-quarter to one-third of HBsAg-seropositive patients. This occurs more frequently in males and in patients infected with genotypes D, C and B. The effort of active HBV replication-triggered immune clearance is the driving force of liver injury and subsequent disease progression in patients with hepatitis B e antigen (HBeAg)-positive or HBeAg-negative hepatitis. Clinical studies have shown that chronic HBV infection in western countries is associated with a higher incidence of cirrhosis, but lower incidence of hepatocellular carcinoma, than in Asian countries. The geographical differences in age at the time of infection and predominant HBV genotype could account for the variance in the natural history of chronic HBV infection; however, some of these differences might actually result from comparisons between cohorts with different age, gender distribution or fibrosis stage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041901     DOI: 10.3851/IMP1621

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  49 in total

Review 1.  Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Genotyping of hepatitis B virus isolates from Lahaul and Spiti district in Himachal Pradesh, India.

Authors:  Brij Sharma; Harshita Katiyar; Deepesh Barall; Neetu Sharma; Shikha Agnihotry; Amit Goel; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2018-06-01

3.  Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.

Authors:  Jennifer Guy; Marion G Peters
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-10

Review 4.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Natural history of chronic hepatitis B: phases in a complex relationship.

Authors:  Catherine M N Croagh; John S Lubel
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 6.  CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated.

Authors:  Bashar M Attar
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-02-25

7.  Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells.

Authors:  Yasuteru Kondo; Osamu Kimura; Yasuhito Tanaka; Masashi Ninomiya; Tomoaki Iwata; Takayuki Kogure; Jun Inoue; Masaya Sugiyama; Tatsuki Morosawa; Yasuyuki Fujisaka; Tooru Shimosegawa
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

Review 8.  Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

Authors:  Dede Sit; Bennur Esen; Ahmet Engin Atay; Hasan Kayabaşı
Journal:  World J Hepatol       Date:  2015-04-18

9.  A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants.

Authors:  Hari Shankar; Demetri Blanas; Kian Bichoupan; Daouda Ndiaye; Ellie Carmody; Valerie Martel-Laferriere; Joan Culpepper-Morgan; Dougles T Dieterich; Andrea D Branch; Mulusew Bekele; Kim Nichols; Ponni V Perumalswami
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

Review 10.  Hepatitis B virus burden in developing countries.

Authors:  Rosa Zampino; Adriana Boemio; Caterina Sagnelli; Loredana Alessio; Luigi Elio Adinolfi; Evangelista Sagnelli; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.